Transplacental transfer of genotoxins and transplacental carcinogenesis. by Autrup, H
Environmental Health Perspectives Supplements
101 (Suppl. 2): 33-38 (1993)
Transpiacental Transfer of Genotoxins and
Transpiacental Carcinogenesis
by Herman Autrup
Anumber ofchemical compounds induce cancer in the offspringofanimals treated with these compounds.
Thefetus issensitive tothetoxicandteratogeniceffectsofchemicals intheearlyembryonicstages,whereas it
is sensitive to carcinogenic effects during late fetal stages. Carcinogens may be direct acting or may require
metabolic oxidation such as those in tobacco smoke. Activation can occur in utero. Animal experiments
indicate that tumors can be initiated in utero, commonly by activation ofcellular proto-oncogenes, and that
promotion can occur after birth by postnatal treatment with tumor promoters. This may have important
implications for humans. The initial peak of cancer incidence during the first 5 years of life may be due to
prenatal exposure of either parent to mutagens, but the role of paternal exposure in relation to childhood
cancer is controversial. There is an increased riskofcancer inchildren whose fathers work in heavy industry
orwhose motherswork in medical ordental services.The exactetiological agents have notbeen unequivocally
identified. Information onhumantransplacental exposure tocarcinogensandgenotoxins islimitedandbased
on measurement of maternal plasma concentrations or analysis of cord blood. nfansplacental transfer of
carcinogens in smoke and smoke-related damage to fetal tissue have been demonstrated. The mycotoxin
aflatoxin B, or its metabolites have been detected in cord blood, as have metabolites of pesticides and
polychlorinatedbiphenyls.Newbiomarkers mayprovideimportant information onthetransplacental transfer
of genotoxic compounds. Recent developments in the field of molecular biology such as polymerase chain
reaction may disclose relevant biological changes occurring in utero as a consequence of exposure to
environmental compounds.
Introduction
More than 600 compounds, mixtures of compounds, or
chemical processes have been evaluated for their carcino-
genic effect in humans by the International Agency for
Research on Cancer, but there was clear evidence for
human carcinogenic risk associated with exposure to only
50 ofthese (1). Some ofthese compounds have teratogenic
or transplacental carcinogenic activity in experimental
animals and therefore maybe considered to be potentially
hazardous to pregnant women. Animal experiments indi-
cate that the fetus is sensitive to the toxic and teratogenic
effects of radiation and chemicals at early embryological
stages, but it is resistant to tumor induction. In contrast,
chemicals have been found to induce tumors at high inci-
dence rates when given during late fetal stages.
Epidemiological data on transplacental carcinogenesis
are limited (Table 1), the first human example being the
induction of vaginal adenocarcinoma following maternal
exposure to diethylstilbestrol during the first trimester
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(2). This tumor does not occur during childhood, butthere
is an increased risk ofits development later in life, albeit
extremely low (3).
The initialpeak ofcancerincidence is duringthe first 5
years oflife, and this may be explained by prenatal expo-
sure of either parent to mutagenic agents. A number of
epidemiological studies have been conducted to evaluate
potentialassociationsbetween the occupational activityof
parent and the risk of cancer in their offspring, but no
clear associations have been established (4,5). Children of
mothers employed in medical and dental care were noted
tohave anelevatedriskofrenal cancerandosteogenicand
soft-tissue sarcomas, whereas children of female nurses
had an elevated risk for cancers at all sites (5). The
handling ofdrugs and exposure to anesthetic agentswere
suggested to be potential risk factors, but the etiological
agents responsible for the cancers were not identified.
Significantlyincreased riskwas also observed in children
offathers employed in heavyindustry such as smiths and
machinists, but the previous suggestions that exposure to
hydrocarbons and lead was a risk factor could not be
supported by the Danish study (5).
Prenatal events can contribute to the occurrence of
canceras aconsequenceofdirectexposureofembryonicor
fetal cells to the carcinogenic agents, or exposure of the
cell itself at a prezygotic stage. The role of paternal
exposure to carcinogens as a risk factor for childhoodH. AUTRUP
Table 1. Epidemiological studies ofperinatal carcinogenesis.
Exposure/occupationa Thmor site Risk Reference
Medical and dental care (F) Renal 2.5* (5)
Nurse (F) All 1.4* (5)
Medical/dental/veterinary All 1.4* (5)
pharmaceutical (M or F)
Pharmacist (M) Leukemia 19.7* (6)
Smiths (M) All 1.6* (5)
Machinists (M) All 1.5* (5)
Smoking (M) Leukemia 2.1 (41)
> 10 cigarettes (M and F) Hematopoietic 1.6* (41)
Hydrocarbons (M) Acute leukemia 2.5* (6)
'F = father's occupation; M = mother's occupation.
*p < 0.05.
cancer is quite controversial and has not been substanti-
ated in animal experiments. Treatment of male rats with
ethylnitrosourea, adirect-actingcarcinogen, upto5weeks
before mating resulted in decreased fecundity but no
increase intumorincidenceintheoffspring(6).Amongthe
most common tumors in infancy and childhood are the
embryonic tumors such as those ofkidney and retina, and
theseshow apatternofdevelopmentthatisconsistentwith
a two-mutational-event sequence. The first mutation can
either be inherited or may be acquired in a somatic cell,
whereas the second event occurs inthetargetsomatic cell.
Carcinogenic mutations generally involve deactivation of
suppressor genes. However, the nature and causes of the
inactivating somatic mutations or chromosomal deletions
have notbeenidentified. Therapid developmentinmolecu-
lar biology and the identification of a number of tumor-
suppressor genes and their deactivation may soonprovide
new information.
Transplacental Carcinogenesis
Carcinogenesis is a multistage process where normal
growth, differentiation, and development have gone out of
control. Carcinogenesis is driven by spontaneous and
carcinogen-induced genetic and epigenetic events. Opera-
tionally, the process has been divided into initiation, pro-
motion, and progression. Timorinitiation involves adirect
effect ofthe carcinogens on DNA, resulting in mutations.
The biological consequence of some of those mutations
mayinvolve altered growth, resistance tocytotoxicity, and
dysregulation of terminal differentiation. The promotion
stage involves a clonal expansion of those cells with the
changedproperties.Anumberofanimalexperiments have
demonstrated that the initiation can take place in utero
with later promotion by treatment of the offspring. The
postnatal exposure to tumor promoters will result in
tumor formation at sites where no tumor would occur
without the application of these promotors. Skin tumors
developed in the descendants of pregnant mice treated
with 7,12-dimethylbenz[a]anthracene (7) followed by
postnatal treatment with 13-tetradecanoylphorbol acetate
(TPA), similar to the classical skin tumor model where
both treatment schedules areperformed postnatally. Thy-
roid follicular tumors developed in rats after prenatal
treatment with the direct-acting carcinogens N-alkyl-
nitrosoureas and postnatal administrations of barbitu-
rates (8). The initiation process is considered irreversible,
in contrast to the promotional events. When Patas
monkeys were treated transplacentallywith the liver car-
cinogen diethylnitrosoamine (DEN), no hepatic tumors
developed. However, treatment ofthe offsprings with the
liver tumorpromotorphenobarbital, starting at4 years of
age, resulted in the rapid appearance of hepatocellular
carcinoma (9). Extrapolation of this information to the
human situation may have some important implications.
Intrauterine exposure to carcinogens may initiate some
cells, but this will result in tumor formation if there is
exposure to tumor promoters later in life.
Carcinogen Metabolism and DNA Repair
Carcinogens present in the environment could be acti-
vatedtotheirbiologicallyactiveforminthematernalliver,
in placenta, or in fetal tissues. The initiation process
involvestheinteractionoftheultimateformofthecarcino-
genwiththe DNAtoform carcinogen-DNAadduct. Upon
replication, or by a faulty DNA repair mechanism, this
damage is transformed into a mutational event such as
point mutations. Due to the high rate of replication and
lack of DNA repair enzymes, animal experiments have
shown that some fetal tissues are highly susceptible to
carcinogenic agents and that this susceptibility is depen-
dent on the gestational period (10). The formation of the
active metabolites will most likely take place in utero by
the embryo orfetus, butactive metabolites maybe formed
in maternal tissue and can be transferred transplacen-
tally. Formation ofthe biologically active metabolites can
be mediated by the cytochrome P-450 mixed-function
oxidase complex, and these enzyme activities have been
demonstrated in human fetal liver from week 12 ofgesta-
tion (11,12) as well as in extrahepatic tissues (12,13). The
cytochrome P-4501A family ofgenes, which is involved in
the activation ofaromatic amines and polycyclic aromatic
hydrocarbons (PAH) to theirultimate carcinogenic forms,
is transcriptionally activated by PAHs and polyhaloge-
nated dioxins and furans. This process is mediated by the
Ah receptor that binds the toxins with high affinity, and
the ligand-receptor complex is subsequently transferred
to the nucleus where itbinds to the xenobiotic-responsive
elements. Animal experiments show that cytochrome
P-4501Agenes areinducibleinfetalratliverbyaPAH,and
that the level ofinduction is dependent on the amount of
theAhreceptor.Thereceptorcouldbeinducedbybarbitu-
rate and PAH (14), andthe concomitant exposure to dioxin
and barbiturate had a synergistic effect on the induction.
TransplacentaltransferinmanofPAHsfoundincigarette
smoke and other environmental toxins that either induce
or bind to the Ah receptor, e.g., dioxins, may induce the
cytochrome P-450IA activities in fetal tissues and hence
modify response ofthe organism to a toxic insult.
Foralongperiod oftimetheplacentawas considered to
be abarrieragainstthetransferoftoxiccompounds tothe
fetus. The placenta has well-developed metabolic defense
mechanisms such as catalase and superoxide dismutase
activities, whichincrease asgestationprogresses, thereby
lowering the concentration of lipoperoxides in the blood
(15). Biotransformation in utero is not only important in
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transplacental carcinogenesis, but also plays a role in the
conversion ofthetoxinstotheirdysmorphogenicform(16).
The amounts ofthe biologically active metabolites depend
onthelevelofP-450 activityand detoxifyingenzymes, and
also on endogenous nonprotein thiols that can protect the
fetus against reactive metabolites and active oxygen radi-
cals. Very little is known about these protective mecha-
nisms in human fetal tissues. The epoxide hydrolase
activity, which is involved in the detoxification of biolog-
ically active epoxides is found at amuch lowerlevelin fetal
than in adult liver (17).
Oncogenes
The detection of transforming cellular oncogenes in
tumors from humans and animals provided the basis for
the hypothesis that cellular oncogenes are the critical
genes involved in carcinogenesis. The ras oncogene was
one ofthe first oncogenes to be detected, and it has been
extensively studied. Members of the ras gene family are
activatedin alargeproportion ofhumantumors. However,
themostdramaticillustration oftheinvolvementoftheras
oncogene comesfromanimaltumorsinducedbychemicals,
where activation of ras has been reported at a high fre-
quencyin a numberoftumors ofepithelial origin. The ras
gene family can be activated by point mutations, and
carcinogen-specific mutations in ras genes canbefound in
tumors produced by different chemical agents (18). A
single treatment with methylnitrosourea during late
stages ofembryonic developmentinduces awidevarietyof
tumors involving cells such as those of neuroectodermal
origin. Thmors derived from the peripheral nervous sys-
tem, but not the central nervous system, contained acti-
vated neu oncogene, whereas the Ha-ras and Ki-ras
oncogenes were activated in the mammary carcinomas
and kidneymesenchymal tumors, respectively. The trans-
placentally activated ras oncogenes contained a G to A
transformation in the second base ofcodon 12 (19), similar
to the mutation seen in tumors initiated with the same
carcinogen during adult life. Using the two-step mouse-
skincarcinogenesis model, tumorsdevelopingaftertrans-
placental initiation with DMBA and postnatal promotion
with TPA contained the Ha-ras oncogene activated at
codon 61. The liver tumors induced by the same protocol
did contain the same type ofmutation (20).
Transplacental exposure of experimental animals to
chemicalcarcinogenscauseanincreaseintumorincidence
notonlyinthe F1 generation butalsointheF2generation,
suggesting possible damage to the germ cells (20). An
increaseintheincidence oflungcancerandmalformations
has been reported in the progeny of parents either of
which had been treated with either X-rays or urethane
beforemating, implying an action ofthecarcinogen onthe
germ cells.
Transplacental Exposure to
Genotoxins
Thetransferofachemical tothefetus atvarious stages
of development can be studied in experimental animals.
However, this type ofinformation forhumans is limited to
theperinatal period and canbe obtainedbysamplingcord
blood. Assessment of exposure to the embryo and fetus
can onlybe roughlybased on maternal plasma concentra-
tions.
Placental transfer has been observed for a number of
different drugs. The ratio ofthe concentrations offetal to
maternal blood depends on the chemical structure ofthe
drugs and ranges from 0.33 for cyclosporin A (21) to
greater than 1 for chloroquine (22). The rate oftransfer,
however, is dependent on a variety of factors including
molecular size and lipophilicity, degree of ionization and
binding to blood components and placental tissue. It is
generally assumed that protein-bound xenobiotic sub-
stances are less likely to pass the placental membrane,
whereas the placenta does not protect against lipophilic
compounds. The rate oftransfer may also depend on the
metabolism ofthe toxin in the placenta itself. The human
placental mixed function oxidase (MFO) system is com-
posed ofseveral different P-450 isozymes. The basal level
of these activities is very low, but can be induced by
substances including constituents ofcigarette smoke (23-
25). The induction of P-450IA1 is mediated by the Ah
receptor, and the level of induction is dependent on the
affinityoftheligandforthereceptor. Ithasbeenproposed
that induction of IAl activities could serve as a placental
markerforexposuretopolychlorinateddibenzofuransand
polychlorinated biphenyls (26). A high level of MFO
activity was detected in placentas from women in Yu-
Cheng where people were accidentally exposed to rice
contaminated with large quantities ofdioxins (27).
The fetal exposure to organochloride pesticides and
polychlorinated biphenyls has been evaluated in anumber
ofstudies by detection ofthe various metabolites in cord
blood samples (28). The levels ofthese compounds in cord
blood samples collected in industrialized nations, where
the use ofthe compounds has been limited or banned, is
lower than in samples collected in developing countries
(29). These compounds are not carcinogenic as such, but
many are potent promoters in experimental animals.
Several carcinogens and teratogens, such as PAHs and
nitrosamines, are present in cigarette smoke. Different
biochemical markers such as cotinine and thiocyanate are
frequently used to assess passive exposure to smoking.
The levels ofthese markers are identical in maternal and
cord blood clearly indicating the compounds in cigarette
smoke arepassingfromthemotherto thefetus. However,
no evidence of increased mutation frequency or sister
chromatid exchanges (SCE) could be detected in cultured
lymphocytes from cord blood (30). The studies on SCE in
human lymphocytes of smokers and nonsmokers have
yieldedconflictingresults.Theeffectofmaternalexposure
to cigarette smoke in the fetus has been studied in a num-
berofanimalstudies.ThenumberofSCE infetalliverwas
increased following exposure to either mainstream or
sidestream smoke, the sidestream being more active (31).
This suggests that exposure to environmental tobacco
smoke may represent a health hazard to the fetus. How-
ever, the available epidemiological dataprovide no conclu-
sive evidence of an effect of maternal smoking during
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pregnancy on the risk of cancer in children (32). An in-
creased level ofcadmium, another component ofcigarette
smoke, was seen in cord blood from smoking mothers
compared to nonsmokers (33), indicating that many toxic
components in cigarette smoke can pass the placental
barrier.
BindingtheactiveformofcompoundstocellularDNAin
fetal tissue would therefore be an indicator offetal expo-
sure tothegenotoxin. Severalsensitivemethodshavebeen
developed to measure these reaction products (34), and
umbilical cord tissues could serve as a good indicator for
transplacental transfer of genotoxins. The 32P-post-
labelingtechnique has been applied to DNAisolated from
fetal tissues from animals treated with different carcino-
gens. The level of adduct was generally higher in the
maternal than in thefetal tissues, which maybe indicative
of maternal metabolism of the carcinogens. The organo-
tropism of carcinogen-DNA adduct formation seen in
maternaltissueswasnotobservedinfetaltissues (35).The
32P-postlabeling assayhas been developed to detectbulky
carcinogen-DNA adduct, and it is possible to detect one
modified base in 108 bases. DNAisolated from the tissues
isdegradedintomonophosphatenucleotidesbyacombina-
tion ofnucleases, and 32p is enzymatically transferred to
the monophosphate nucleotides to form diphosphates
which are separated by four-dimensional thin layer chro-
motography. Anumberofstudies have demonstratedhigh
levels of carcinogen-modified DNA in placenta from
smokers (36), and in lung and liver DNA isolated from
aborted fetuses (37). The presence of adduct in fetal
tissues indicates the transplacental transfer of the car-
cinogens or their metabolites. In a recent study it was
reported that the adduct level was significantly higher in
umbilical artery and vein tissue from smokers than non-
smokers (Table 2). The presence ofadduct in tissues from
nonsmokingmothers suggests thatpassive smoking com-
pounds or other general pollutants can pass the placental
barrier (Hansen etal., manuscriptsubmitted). Thelevel of
adduct was significantly higher in the maternal tissues
than in the fetal tissues. The observation thatthe carcino-
gen-DNA adduct level was higher in the umbilical cord
artery than in the vein suggests that fetal metabolism of
thecarcinogenstakesplace. Oneofthemajorcarcinogenic
components incigarette smokeisbenzo[a]pyrene. Using a
combination of immunoaffinity chromatography linked
with synchronous fluorescence spectrophotometry, the
presence of benzo[a]pyrene diol epoxide adduct was
detected in human placenta DNA, and the chemical iden-
Table 2. nfansplacental transfer ofsmoking-related carcinogens:
relative adduct levels detected by 32P-postlabeling.
Tissue Smokers Nonsmokers
All 42.8 ± 11.6 19.7 ± 4.2* (p = 0.021)
Maternal 62.6 ± 29.2t (p = 0.089) 29.2 ± 6.8t (p = 0.061)
Fetal 31.4 ± 12.4 14.7 ± 5.1* (p = 0.089)
Vein 23.5 ± 11 7.3 ± 2.3
Artery 39.4 ± 23 22.9 ± 10
*Significantly different from smokers.
tSignificantly different from fetal tissue.
tSignificantly different from fetal tissue.
Table 3. ¶ransplacental exposure to 4-aminobiphenyl in smokers:
aromatic amine-hemoglobin adducts (42).
Smokers Nonsmokers
Fetal 92 ± 54 pg/g Hb 17 ± 33 pg/g Hb
Maternal 1.83 ± 1.08 pg/g Hb 22 ± 8 pg/g Hb
p 0.02 0.6
Maternal/fetal ratio 24 19
HB, hemoglobin.
titywasverifiedbyGC-MS (38). Bindingto hemoglobinis
a good biomarker for the exposure to aromatic amines.
4-Aminobiphenyl adducts couldbe detected inbothmater-
nal and cord blood (Table 3).
Aflatoxin B1, produced by Aspergillus flavus and A.
paraciticus, is commonlyfound as a contaminant ofmany
staple food commodities in the tropics. This compound is a
potenthumancarcinogen, and exposure in utero hasbeen
suggested to play a role in the development of primary
hepatocellular carcinomas in young children in Kenya.
Analysis of cord blood samples from Africans (39) and
Asians (40) showedthe presence ofaflatoxinB1 and one of
its metabolites, aflatoxin M1. The relative frequency of
aflatoxin-positive cord blood samples depended on geo-
graphical location and seasonal variation. A higher fre-
quencyofpositive sampleswas seen in cordblood samples
collected during the wetperiod compared to the cold, dry
months. This seasonal variation in frequency and level of
aflatoxin detection accords with an increase in aflatoxin
contamination of foods during periods of high tempera-
ture and humidity. In Kenya, the mean birth weight of
females born to aflatoxin-positive mothers was 255 g less
than the mean birth weight of females born to aflatoxin-
negative mothers (39).
Conclusion
We are living in a chemical world and are continuously
exposed to a large number of chemical compounds that
mayadverselyaffectourhealth. Someofthese compounds
may be teratogenic, may initiate cancer that will develop
later in adult life, or may result in delayed effects on
descendants. Little information on human exposure to
genotoxic agents is available, whereas a number ofpapers
have described the effects of heavy metals. A number of
new analytical techniques have been developed to assess
human exposure to genotoxic compounds, and these could
easily be applied to human fetal tissues or cord blood. As
placental tissue is easily available, this tissue could serve
as a surrogate tissue for the assessment offetal exposure
to genotoxic carcinogens.
Induction of cytochrome P-450 activity in the placenta
may serve as an indirect measure of the exposure to
compounds that are not in themselves genotoxic but may
influence the carcinogenic process.
Developments in this area ofmolecular biology such as
polymerase chain reaction (PCR) in combination with
assays to detect mutations make it possible to study the
activation of proto-oncogenes and cancer-suppressor
genes in different fetal tissues. This could enable identifi-
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cation oflesions that may have the potential ofleading to
the development of cancer and testing for such lesions
couldbeperformed following exposure to compoundswith
known tumor-promoting activity. Characterization ofthe
type ofmutation may suggest the identity ofthe chemical
agent responsible for the mutation.
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